APRE
Aprea Therapeutics, Inc.
5.20
-
0.11
2.07%
0 x 0.00
0 x 0.00
bid
ask
0 @ 04:00 PM
5.31+0.11 (2.12%)
Bearish
5
Bullish
19
sentiment
5.05
day range
5.20
2.89
52 week range
8.46
Prev Close5.31
Open5.20
Low5.05
High5.20
Volume4.83K
Avg. Volume32.91K
Market Cap28.24M
Inst. Own17.70%
Beta0.17
Short Ratio6.71
Div & Yield0.00 /
EPS-3.95
P/E0.00
1yr Target15.67
50day MA6.40
200day MA4.80
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 | globenewswire.com • |
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference | globenewswire.com • |
Aprea Therapeutics to Present at BIO International Convention | globenewswire.com • |
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now | zacks.com • |
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy | zacks.com • |
Best Penny Stocks To Buy? 4 To Watch In January 2023 | pennystocks.com • |
Profile
...
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | -0.78 | N/A | N/A | N/A |
2024-03-26 | 2023-12 | -0.56 | -0.92 | -0.36 | -64.29% |
2023-11-09 | 2023-09 | -1.08 | -0.86 | 0.22 | 20.37% |
2023-11-09 | 2023-09 | -1.08 | N/A | N/A | N/A |
2023-08-10 | 2023-06 | -1.43 | -0.87 | 0.56 | 39.16% |
2023-08-10 | 2023-06 | -1.43 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-09 | Maxim Group | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-07-27 | COIANTE SCOTT M | Chief Financial Officer | 145.07K | Stock Award(Grant) |
2023-08-22 | DUEY MARC | Director | 209.48K | Stock Award(Grant) |
2024-03-27 | GILAD OREN PH.D. | Chief Executive Officer | 333.30K | Stock Award(Grant) |
2023-08-22 | GRISSINGER MICHAEL J. | Director | 799.00 | Stock Award(Grant) |
2024-03-27 | HAMILL JOHN P | Chief Financial Officer | 18.87K | Stock Award(Grant) |
2024-03-12 | HENNEMAN JOHN BELL III | Director | 8.14K | Purchase |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | AIGH Capital Management LLC | 349.30K | 1.10M | 9.35% |
2023-06-29 | Sio Capital Management, LLC | 280.00K | 882.00K | 7.49% |
2023-06-29 | Walleye Capital LLC | 93.63K | 294.93K | 2.51% |
2023-06-29 | Worth Venture Partners, Llc | 87.17K | 274.58K | 2.33% |
2023-06-29 | Geode Capital Management, LLC | 23.59K | 74.31K | 0.63% |
2023-06-29 | Morgan Stanley | 15.28K | 48.14K | 0.41% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 9.38K | 29.53K | 0.25% |
2023-05-30 | Fidelity Extended Market Index Fund | 5.11K | 19.68K | 0.14% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.99K | 15.72K | 0.13% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.10K | 4.24K | 0.03% |
2023-06-29 | Vanguard Institutional Index-Inst Total Stock Market Ind | 1.14K | 3.58K | 0.03% |
2023-05-30 | Fidelity Total Market Index Fund | 833.00 | 3.21K | 0.02% |
Split
...
Split | Date |
---|---|
1 : 20 | 2023-02-13 |
1 : 1000 | 2018-12-27 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
globenewswire.com • -
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
globenewswire.com • -
Aprea Therapeutics to Present at BIO International Convention
globenewswire.com • -
Best Penny Stocks To Buy? 4 To Watch In January 2023
pennystocks.com • -
Why The Stock Market Is Down Today & 4 Penny Stocks To Watch
pennystocks.com • -
Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target
investorplace.com • -
Got $5 to Spend on Penny Stocks? Check These 4 Out
pennystocks.com • -
APRE Stock: Why It Increased Today
pulse2.com • -
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
pennystocks.com • -
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
globenewswire.com • -
Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded
pennystocks.com • -
APRE Stock Price Increases Over 40%: Why It Happened
pulse2.com • -
Why Aprea Therapeutics Shares Are Surging Today
benzinga.com • -
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
globenewswire.com • -
APRE Stock Price: $6 Target By Morgan Stanley
pulse2.com • -
Is Aprea Therapeutics Doomed?
247wallst.com • -
3 Stocks with Jaw-Dropping Growth Potential
fool.com • -
Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020
businesswire.com • -
A new revolutionary alternative for the people of Venezuela
morningstaronline.co.uk • -
Power Rental Market Research Report – Global Forecast Till 2025
marketwatch.com • -
Atlas (ATCO) CEO, Bing Chen on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com • -
How to take a high-interest loan and skip the debt cycle
abcnews.go.com • -
Aprea Therapeutics Cancer Therapy Platform Is Promising
seekingalpha.com • -
Adil Erradi tasked to guide APR to group stage in Champions League
newtimes.co.rw • -
Parametric Portfolio Associates LLC Takes $777,000 Position in Aprea Therapeutics (NASDAQ:APRE)
thelincolnianonline.com • -
NIRI Chicago Elects 2020-2021 Officers and Directors
businesswire.com • -
Striker Bigirimana joins Rayon on two-year deal
newtimes.co.rw • -
How Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry
finance.yahoo.com • -
We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
finance.yahoo.com • -
Basketball: IPRC-Kigali keen about playoffs spot
newtimes.co.rw • -
Goalie Kwizera admits he is in talks with Rayon
newtimes.co.rw • -
How setter Igihozo defied odds on her way to volleyball stardom
newtimes.co.rw • -
APREA seeks RBI nod for overseas funds debt investment in REITs, InvITs
economictimes.indiatimes.com • -
World's First Bottled Water Launches with 100% Certified Ocean-Bound Plastic
plasticstoday.com • -
CFPB issues proposals to revise QM rule, extend GSE patch
americanbanker.com • -
How To Get A Mortgage: 7 Steps To Success
forbes.com • -
Should You Use One Credit Card To Pay Off Another?
forbes.com • -
NewsCrypto to Change The Cryptocurrency Staking Game? | BTCMANAGER
btcmanager.com • -
Aprea Therapeutics (NASDAQ:APRE) Director Scott M. Rocklage Sells 245,000 Shares
thelincolnianonline.com • -
Midfielder Mukunzi believes he still has room for improvement
newtimes.co.rw • -
Amazon Offers A Line Of Credit To Select Sellers
forbes.com • -
Innocent Nshuti: Tracing the meteoric rise of the APR star
newtimes.co.rw • -
Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE)
finance.yahoo.com • -
Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher
finance.yahoo.com • -
How To Transfer Your Credit Card Balance
gobankingrates.com •